Today, Cambridge, MA-based Zafgen said that it is banking $45 million from a Series E round, adding a group of new investors that includes RA Capital Management, Brookside Capital, Venrock, Alta Partners, an undisclosed blue chip investor and a...
Danish drug maker Novo Nordisk said it expects to file for U.S. regulatory approval for its new obesity drug "within weeks," in a bid to diversify a product portfolio that is focused on diabetes treatments.
(MedPage Today) -- Metabolically healthy obese people have a long-term increased risk for death and cardiovascular events, suggesting there is no such thing as benign obesity, according to a meta-analysis.
Allergan, Inc. (NYSE:AGN) today announced that it has completed the sale
of its obesity intervention business to Apollo Endosurgery, Inc. Under
the terms of the agreement, which was first announced on October 29,
(MedPage Today) -- Interim data from a cardiovascular safety study of an investigational weight-loss agent have met FDA criteria, and drugmaker Orexigen Therapeutics will seek to resubmit the drug for U.S. approval.